- Home
- STSS vs CALC Comparison
STSS vs CALC Comparison
Compare STSS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | CALC |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 91.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | CALC |
|---|---|---|
| Price | $2.27 | $6.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 258.3K | 144.6K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $306,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $1.42 |
| 52 Week High | $690.01 | $6.40 |
Technical Indicators
Market Signals| Indicator | STSS | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 76.69 |
| Support Level | $2.01 | $4.64 |
| Resistance Level | $2.90 | $5.34 |
| Average True Range (ATR) | 0.28 | 0.51 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 18.44 | 90.04 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.